Refine
Year of publication
- 2020 (2)
Document type
- Report (2)
Language
- English (2)
Has full text
- Yes (2)
Is part of the Bibliography
- No (2)
Keywords
- 2030 (1)
- Cost effectiveness (1)
- Electric cars (1)
- Future cars (1)
- Germany (1)
- Hybrid cars (1)
- Individual medicine (1)
- Leukemia (1)
- Prostata cancer (1)
- Scenario planning (1)
Course of studies
Germany has a long history in the car sector. However, today’s car industry is drastically changing, triggered by the accelerated rise of new technologies, sustainability policies and changing consumer preferences. The purpose of this research project is to forecast, by using the scenario planning software INKA 4, the future of cars in Germany in 2035. The research project focused mainly on cars based on internal combustion engines (ICE), fuel cell vehicles (FCV), battery electric vehicles (BEV) and Hybrid electric vehicles (HEV) and their charging infrastructure in Germany. Also, the future of autonomous driving vehicles, public transportation and carsharing in Germany were taken into consideration. Considering these factors following four areas of influence were chosen: Technology, Economics, Politics and Social. Within these areas of influence thirteen input factors (descriptors) were defined by research on current literature. The results show three distinct scenarios that reflect a possible shift towards electric mobility, autonomous driving, and an increase in the use of car sharing.
Key findings
The future of cars in Germany is affected by four areas of influence: Technology, Economics, Politics and Social. Among those four areas, a total of thirteen descriptors were selected as an input for the scenario building.
With the software INKA 4 five different scenarios were generated. Three distinctive scenarios were chosen and described to outline the future of cars in Germany in 2035.
It is highly probable that the future cars will be electrified and autonomous and that shared mobility will increase. The extent of the aforementioned change until 2035 depends highly on the German government and customer preferences.
Individual medicine gained increasing popularity in the medical industry in the past years. Especially oncology plays a major role in individual medicine, as significant research has been done in this area in the last decade. In order to provide individual treatment to patients, individualized medicine in cancer therapy uses molecular genetic examination of blood or tumor tissue.
This paper discusses individual treatment approaches for the selected diseases of prostate cancer and leukemia. Individual medicine in prostate cancer is still considered to be in its infancy whereas in leukemia it is already advanced. Conventional treatment in prostate cancer is highly standardized and well-developed and thus, individual approaches in PCa are not yet well-established or well-researched. Therefore, the relevance of individual treatments in prostate cancer is still to be discussed. In contrast to that leukemia has a promising future in the area of individualized medicine. However, individualized treatments are still very expensive and health insurances only cover a limited amount of financial expenses. As genetic testing is becoming more significant and is likely to be used more often in the future, the cost for individual treatments are expected to decrease over time. Also, this paper suggests future implications for the application of individual medicine in Germany in the areas of health care promotion, disease prevention and disease management until the year 2030.
Highlights of the paper:
• Individual medicine in leukemia is already well-established, however necessity of individual approaches in prostate cancer is discussed
• Individual medicine is currently very cost-intensive but increases the quality of life and the lifespan.
• In order to implement individual medicine in the future it is anticipated to improve health care promotion, disease prevention and disease management.